These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 26660436)

  • 1. ▼Naloxegol for opioid-induced constipation.
    Drug Ther Bull; 2015 Dec; 53(12):138-40. PubMed ID: 26660436
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Naloxegol: a review of its use in patients with opioid-induced constipation.
    Garnock-Jones KP
    Drugs; 2015 Mar; 75(4):419-25. PubMed ID: 25666542
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Naloxegol (Movantik) for opioid-induced constipation.
    Med Lett Drugs Ther; 2015 Sep; 57(1478):135-7. PubMed ID: 26393826
    [No Abstract]   [Full Text] [Related]  

  • 4. Naloxegol: the first orally administered, peripherally acting, mu opioid receptor antagonist, approved for the treatment of opioid-induced constipation.
    Corsetti M; Tack J
    Drugs Today (Barc); 2015 Aug; 51(8):479-89. PubMed ID: 26380386
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel Oral Therapies for Opioid-induced Bowel Dysfunction in Patients with Chronic Noncancer Pain.
    Holder RM; Rhee D
    Pharmacotherapy; 2016 Mar; 36(3):287-99. PubMed ID: 26945548
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiovascular Safety of the Selective μ-Opioid Receptor Antagonist Naloxegol: A Novel Therapy for Opioid-Induced Constipation.
    White WB; Kowey P; Diva U; Sostek M; Tummala R
    J Cardiovasc Pharmacol Ther; 2018 Jul; 23(4):309-317. PubMed ID: 29504415
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Naloxegol for the treatment of opioid-induced constipation.
    Tack J; Corsetti M
    Expert Rev Gastroenterol Hepatol; 2014 Nov; 8(8):855-61. PubMed ID: 25220391
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Naloxegol: A Novel Therapy in the Management of Opioid-Induced Constipation.
    Jones R; Prommer E; Backstedt D
    Am J Hosp Palliat Care; 2016 Nov; 33(9):875-880. PubMed ID: 26150678
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomised clinical trial: the long-term safety and tolerability of naloxegol in patients with pain and opioid-induced constipation.
    Webster L; Chey WD; Tack J; Lappalainen J; Diva U; Sostek M
    Aliment Pharmacol Ther; 2014 Oct; 40(7):771-9. PubMed ID: 25112584
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Naloxegol oxalate, pirfenidone, and nintedanib.
    Hussar DA; Jeon MM
    J Am Pharm Assoc (2003); 2015; 55(4):461-3. PubMed ID: 26161491
    [No Abstract]   [Full Text] [Related]  

  • 11. Naloxegol for managing opioid-induced constipation.
    Shelton KN; Clements JN
    JAAPA; 2017 Sep; 30(9):51-53. PubMed ID: 28858018
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of Treatment with Naloxegol for Opioid-Induced Constipation on Patients' Health State Utility.
    Lawson R; King F; Marsh K; Altincatal A; Cimen A
    Adv Ther; 2016 Aug; 33(8):1331-46. PubMed ID: 27342744
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacometric Modeling of Naloxegol Efficacy and Safety: Impact on Dose and Label.
    Al-Huniti N; Zhou D; Xu H; Aksenov S; Bui KH; Fox R; Helmlinger G; Stanski D
    Clin Pharmacol Ther; 2017 Nov; 102(5):741-744. PubMed ID: 28548207
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treating Opioid-Induced Constipation in Older Adults: New Options.
    Sani H; Mahan RJ
    Consult Pharm; 2015 Oct; 30(10):612-5. PubMed ID: 26450143
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A 12-week extension study to assess the safety and tolerability of naloxegol in patients with noncancer pain and opioid-induced constipation.
    Webster L; Tummala R; Diva U; Lappalainen J
    J Opioid Manag; 2016; 12(6):405-419. PubMed ID: 28059433
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluating naloxegol for the treatment of opioid-induced constipation.
    Daniali M; Nikfar S; Abdollahi M
    Expert Opin Pharmacother; 2020 Jun; 21(8):883-891. PubMed ID: 32129103
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Naloxegol for opioid-induced constipation in patients with noncancer pain.
    Chey WD; Webster L; Sostek M; Lappalainen J; Barker PN; Tack J
    N Engl J Med; 2014 Jun; 370(25):2387-96. PubMed ID: 24896818
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Naloxegol: A Review of Clinical Trials and Applications to Practice.
    Dume R; Shuman M
    Orthop Nurs; 2019; 38(3):209-211. PubMed ID: 31124873
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of naloxegol for opioid-induced constipation assessed by specific opioid medication, opioid dose, and duration of opioid use.
    Nalamachu S; Gudin J; Datto C; Coyne K; Poon JL; Hu Y
    J Opioid Manag; 2018; 14(3):211-221. PubMed ID: 30044486
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Opioid-Induced Constipation Part 2: Newer Therapies #295.
    Badke A; Rosielle DA
    J Palliat Med; 2015 Oct; 18(10):893-4. PubMed ID: 26439728
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.